All In Biotech

Drug Trial Radar · NCT02311231

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Last checked: Nov 20, 2026Latest source record: May 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,012 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,012

Actual

Start

Jun 2014

Primary completion

Mar 2017

Study completion Mar 2017

Sponsor

Lead sponsor
Uppsala UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lund University
First posted
Dec 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this trial we test the hypothesis that PCI and bivalirudin is superior to heparin alone (according to local protocol) in reducing death, MI, and major bleeding in patients with NSTEMI or STEMI at 180 days (primary end point), treated with ticagrelor or prasugrel.

Conditions

  • ST-segment Elevation Myocardial Infarction
  • Non ST-segment Elevation Myocardial Infarction

Interventions

  • bivalirudinDrug

    Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.

  • HeparinDrug

    Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death, Myocardial infarction and major bleeding eventTime frame: 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lund University

    Lund, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.